Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

ARTICLE | Clinical News

Alnylam, Ionis fall after Pfizer's TTR cardiomyopathy readout

Elizabeth S. Eaton

March 30, 2018 8:30 PM UTC

Pfizer Inc. (NYSE:PFE) said tafamidis meglumine met the primary endpoint in the Phase III ATTR-ACT trial to treat transthyretin (TTR) cardiomyopathy. Compared with placebo, the therapy reduced a combination of all-cause mortality and frequency of cardiovascular-related hospitalizations at 30 months.

Tafamidis is a small molecule that stabilizes the TTR protein and prevents its misfolding...

Get Unlimited Access

Continue reading with a free trial.

Start a Free Trial Log In

Or Purchase This Article

BCIQ Company Profiles

Alnylam Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc.

Pfizer Inc.

BCIQ Target Profiles